Abstract This paper describes the alginate encapsulation of preformed high-density 3-D HepG2 cell aggregates that guarantees good maintenance of liverspecific biomarker expression. The process involves forming a high-density (≥7×10 4 cells/aggregate) discoid 3-D cell aggregate in an ultrasound trap, which is subsequently recovered and encapsulated in alginate/CaCl 2 hydrogel. Glucose secretion/consumption, lactate release, detoxifying enzyme capacity, cytokeratin-18 expression as well as hypoxia were characterized in encapsulated 3-D HepG2 aggregates over 10 days in culture. Encapsulated 3-D HepG2 aggregates released glucose into the media, although this ability was exhibited only after 1 day in culture and was subsequently lost over the ensuing 9 days. In contrast, lactate was constantly released into the media. Significantly more lactate was secreted after 3 days in culture indicating a more hypoxic environment and hence a higher rate of anaerobic glycolysis. Aggregates consistently expressed cytokeratin-18. Cytochrome P450-1A1 activity reached a maximum on day 1 of culture followed by a progressive reduction to basal levels, while P450-3A4 activity was up-regulated in a time-dependent manner reaching a peak on day 7 in culture. Glutathione-S-transferase activity, on the other hand, was at more physiological levels and remained constant over the 10-day culture period. The ultrasound trap allowed the rapid (within 5 min) generation of uniformly shaped and sized aggregates. The results reported here suggest that ultrasound-formed 3-D HepG2 aggregates can serve as alternative in vitro models providing a quick outlook on toxicity, in a tissuemimetic manner, thus offering the future option of a cost-effective screening platform for pharmaceutical development.
Introduction
Given current developments in drug discovery and synthesis, it is of paramount importance to develop an efficient high-throughput drug screening and testing system that will faithfully mimic tissues and organs, in particular the liver, in vivo (Zhang et al. 2005) , as detoxification and activation processes of compounds are studied most optimally in liver cells. Conventional animal experiments are expensive and use a large number of animals. It is therefore essential, in order to maintain cellular functions, to construct and maintain in culture high-density 3-D liver-mimetic structures (Hongo et al. 2005) as in vitro surrogates for animalbased toxicity testing (Groneberg et al. 2002) .
Such liver-mimetic structures would be most useful if they employ primary hepatocytes or a humanderived hepatocyte cell line (Wilkening et al. 2003) . Primary cultures of hepatocytes are undoubtedly the most useful cell lines as human liver models, as their drug-metabolizing enzyme activity is high. Their limited availability, however, together with the complexity of their isolation from animal or human liver, makes experiments with primary cells complicated and time consuming. More importantly, the rapid loss of liver-specific functions in traditional monolayer culture of liver cells soon after their isolation, as well as remarkable inter-individual differences that make results non-reproducible, limits their application in drug screening (Allen and Bhatia 2002; Horiuchi et al. 2009 ). Due to the high interest within the pharmaceutical industry to examine compounds as early as possible and with relatively small quantities of compounds (Schoonen et al. 2005) , the HepG2 human hepatocellular carcinoma cell line is a very valuable, effective, and reasonable compromise between ease of culture and production of key enzymes (Camp and Capitano 2007) providing a quick outlook on toxicity. Interference with normal cell physiology can be a simple cell toxicity marker (Schoonen et al. 2005) .
3-D culture systems that can maintain stable longterm functions of liver cells typically include the pellet culture (Ong et al. 2006) , spheroid culture induced by seeding on weakly adherent surfaces or soft gels, such as poly HEMA coatings (Chia et al. 2000 (Chia et al. , 2002 , alginate sponges (Glicklis et al. 2000; Seo et al. 2006) and Matrigel , or by preventing cell attachment by suspension culture in spinner flasks (Gwak et al. 2006) . However, spheroids greater than 100 µm in diameter suffer from oxygen and nutrition delivery limitations to their central core, thus making them unsuitable for longterm cultures . Smaller aggregates can be obtained in Matrigel, although the potential tumorigenicity and immunogenicity, as well as the poorly defined composition and potential batch-to-batch variability of this material, limit its use for in vitro drug toxicity studies . Furthermore, pellet and spheroid cultures often require a long aggregation time (days or weeks; Xu et al. 2003; Jin et al. 2007; Rieke et al. 2008) .
Microencapsulation is one of the promising strategies for tissue engineering (and cellular therapy) to develop a 3-D growth pattern of cells to mimic tissue in vivo (Zhang et al. 2005) . We have previously reported (Bazou et al. 2008 ) on a gel encapsulation technique that departs from the minimum surface area to volume restriction of spherical microcapsules and allows gelation of preformed high-density 3-D HepG2 cell aggregates. This rapid (within 5 min) process involves forming a discoid (i.e., aggregate thickness is 10-12 cell layers deep at the center of the aggregate while it progressively decreases at the aggregate's edges to a "one-cell" layer deep) 3-D HepG2 cell aggregate in an ultrasound standing wave trap (USWT), which is subsequently recovered and encapsulated in alginate/CaCl 2 hydrogel. Briefly, the USWT is an ultrasound resonator where the acoustic path length in the cell suspension is a single half wavelength. The resonator has a pressure node plane half way through the cell suspension and parallel to the transducer (Bazou et al. 2005a, b) . The cell trap exploits the fact that particles and cells in general experience an axial direct acoustic radiation force when in an ultrasound standing wave field. This force drives them towards a node plane (cells normally go to a pressure node). Cells then move, within that plane, to accumulate at the center of the field, i.e. at the nodal plane, to form 2-D (Coakley et al. 2004; Bazou et al. 2005a Bazou et al. , b, 2006 Edwards et al. 2007 ) and 3-D (Liu et al. 2007; Bazou et al. 2008) aggregates in suspension away from the influence of solid substrata. Some technical advantages of the encapsulated system presented here include: (a) ultrasound-formed aggregates are 3-D with extensive cell-cell contacts (Bazou et al. 2008) , thus more closely reflect the in vivo situation with regard to cell shape and cellular environment (Beningo et al. 2004); (b) aggregates in the ultrasound trap are formed very rapidly (within 5 min; Bazou et al. 2005a) ; and (c) alginate encapsulation provides stability and so allowing for transport and mechanical stress (Ringel et al. 2005 ).
An important step towards the promotion of the application of this model as an alternative drug toxicity cell system is the appreciation and establishment of the biochemical characteristics of ultrasoundformed encapsulated 3-D HepG2 aggregates during their maintenance in culture. Liu et al. (2007) have addressed some properties of ultrasound-formed 3-D aggregates (e.g., proliferation, albumin secretion, EROD activity), but these aggregates were not encapsulated, while in our previously published proof-of-concept study (Bazou et al. 2008) , parameters such as aggregate viability, proliferation, and cytoskeletal architecture were investigated. In the latter report, aggregates remained 70-80% viable over 10 days in culture, while their proliferative activity resulted in the doubling of the aggregate cell number (Bazou et al. 2008 ).
The present study aims at providing a more complete view of the biochemical status of highdensity 3-D encapsulated HepG2 aggregates, a cell system that has not been previously fully characterized. Particular attention is paid in CYP450-3A4 (the predominant CYP450-3A isoform expressed in adult human liver and the major phase I xenobiotic metabolizing enzyme for several drugs) and glutathione-S-transferase (involved in phase II metabolism) activities, glucose and lactate release, hypoxia as well as C-18 (a protein with characteristic localisation in the adult liver) expression over 10 days in culture.
Materials and methods

Culture of HepG2 cells
HepG2 cells (European Collection of Cell Cultures Association (ECCA), Salisbury, Wiltshire, UK), were maintained at 37°C under an atmosphere of 95% air and 5% CO 2 in minimum essential medium (MEMEagle) containing 2 mM L-glutamine and supplemented with 10% v/v fetal bovine serum, 1% v/v non-essential amino acids, 100 U/ml penicillin, and 100 µg/ml streptomycin (all purchased from Invitrogen, UK). At confluence, cells were washed with phosphate buffered saline (PBS) and then treated with Accutase (Sigma, UK) for 15 min to release cells from the culture flask surface. Cells were filtered through a 40-μm Nitex Cell Strainer (BD Biosciences, Oxford, UK) to ensure a single cell suspension. Cells were then pelleted by centrifugation at 2,000 rpm for 5 min, resuspended in serum-free MEM containing 50 μM Hepes buffer (Sigma, UK), counted, and finally diluted to 4×10 6 cells/ml.
Ultrasound trap
The ultrasound trap had three essential features: a transducer (Ferroperm, Kvistgard, Denmark) in a housing of radial symmetry, an aqueous phase, and a reflector that provided optical access from above, as previously described (Bazou et al. 2005a, b) . The trap was driven at 2.23 MHz with a function generator (Hewlett Packard 33120A, UK). The acoustic pressure amplitude (P 0 ) estimated as described by Khanna et al. (2003) was 0.85 MPa (corresponding to 20 V p-p ) for the first 1 min of ultrasound initiation and subsequently reduced to 0.09 MPa (i.e., 3.5 V p-p , the level at which the acoustic radiation force just balanced the gravitational force on the aggregate and thus maintained the aggregate in suspension) for the remaining 4 min of aggregate levitation in the trap.
Alginate hydrogel preparation and encapsulation of 3-D HepG2 cell aggregates
The hydrogel was prepared using 2% (w/v) Pronova (UP MVM) alginate (NovaMatrixTM, Drammen, Norway), mixed at a ratio of 1:1 with 5 mM CaCl 2 (Sigma, UK). The ultrasound trap was, for all experiments described in this study, placed into the tissue culture cabinet to ensure sterility of the samples. A stereomicroscope (Swift Instruments International, USA), on which the ultrasound trap was placed, was also inserted into the tissue culture cabinet to monitor the aggregate growth process. Formation and encapsulation of aggregates proceeded as follows: cell suspension was introduced into the trap at room temperature with a sterile 2-ml syringe (Plastipak, Becton Dickinson, UK). The acoustic field was initiated and aggregates were allowed to form. The ultrasound field was switched off after 5 min and aggregates were slowly recovered from the trap with the syringe. They were then immersed in 100 μl of hydrogel contained in the wells of a 96-well plate (one aggregate per well) and 100 μl of serum-free MEM medium (Hepes-buffered) was finally added to the wells (Bazou et al. 2008) .
Non-encapsulated 3-D HepG2 aggregates in suspension served as a control; in this case, the 96-well tissue culture plates were pre-coated with 0.5 ml of 2.5% poly (2-hydroxyethyl methacrylate (Sigma, UK) in 95% ethanol, prior to aggregate seeding. The serum-free MEM medium (Hepes-buffered; 200 μl) was finally added to each well. Aggregates were maintained in culture at 37°C/5% CO 2 for a period of 10 days. Cell culture medium was replaced every 3 days.
Immunofluorescence detection of hypoxia inducible factor-1 alpha On days 0, 1, 3, 7, and 10 in culture, encapsulated and control 3-D HepG2 cell aggregates were carefully removed from the wells of the culture plate and placed on a HistoBond microscope slide (RA Lamb, UK). Samples were then fixed with 90% ethanol and subsequently blocked at room temperature with goat serum (DAKO, UK) at 1:20 dilution in PBS and incubated with the primary antibody (mouse monoclonal anti-HIF-1α, 4 µg/ml, clone H1alpha67, Novus Biologicals, Inc, USA) overnight at 4°C. After washing in PBS, samples were incubated with FITC-conjugated anti-mouse IgG (1:100, Sigma, UK). The slides were then incubated at room temperature in the dark for 1 h, rinsed, and mounted in propidium iodide (PI)-Vectashield (Vector Labs, UK). 3-D HepG2 cell aggregates (encapsulated and control) maintained in culture for 10 days in a hypoxic workstation (Invivo 2 400, 5% O 2 , 5% CO 2 , Ruskinn Technology Ltd, UK) served as the control. Fixation and staining of the hypoxic aggregates proceeded as described earlier.
Immunofluorescence detection of cytokeratin-18
On days 0, 1, 3, 7, and 10 in culture, encapsulated and control 3-D HepG2 cell aggregates were carefully removed from the wells of the culture plate and placed on a HistoBond microscope slide (RA Lamb). Samples were then fixed with 90% ethanol and subsequently blocked at room temperature with goat serum (DAKO, UK) at 1:20 dilution in PBS and incubated with cytokeratin-18 (C-18)-FITC-conjugated mouse monoclonal antibody (10 μg/ml; clone DC-10, AbCAM, UK) for 1 h. Samples were then rinsed in saline and mounted in PI-Vectashield.
Confocal microscopy
Specimens were examined using a Leica TCS SP2 AOBS spectral confocal laser scanning microscope (Leica Microsystems, Heidelberg GmbH) that was controlled via a standard Pentium PC running Leica Confocal Software. Z-stacks of optical sections were taken through the entire volume of the aggregates at 1 µm intervals (unless otherwise stated) using appropriate excitation and emission settings for simultaneous dual channel recordings of FITC conjugate (hypoxia inducible factor-1 alpha (HIF-1α) and C-18 staining) and propidium iodide (nuclear staining).
Glucose consumption and lactate release in encapsulated 3-D HepG2 aggregates
Glucose concentration and lactate secretion in encapsulated and control, non-encapsulated 3-D HepG2 aggregates were quantified using the glucose and lactate assay kits (Biovision, CA, USA). The glucose assay kit is a colorimetric assay that quantitatively measures glucose levels in culture medium. In the lactate assay kit, lactate is oxidized by lactate oxidase to generate a product, which interacts with a lactate probe to produce color; this kit provides a convenient means for detecting lactate in culture medium.
On days 0, 1, 3, 7, and 10 in culture, 100 μl of culture media was harvested from the wells containing the control and encapsulated aggregates, separated in two 50-μl samples and placed in separate new 96-well plates. Fifty microliters of the reaction mixtures (provided by the glucose and lactate assay kits) was added to the respective wells. The plates were then incubated for 30 min at 37°C in the dark. The absorbance of the samples was measured at 570 nm using a microtiter plate reader (Anthos Lab Instruments).
Cytochrome P450-1A1 and P450-3A4 activities in encapsulated 3-D HepG2 aggregates CYP450-1A1 and P450-3A4 activities in encapsulated and control (non-encapsulated) 3-D HepG2 aggregates were quantified using the P450-Glo™ assay kits (Promega, Madison, WI, USA). On days 0, 1, 3, 7, and 10 in culture, cell culture medium was replaced with 100 µl culture medium containing 5 µM of the inducer 3-methylcholanthrene (3-MC; Sigma, UK) and 25 µM of the inducer rifampicin (RIF; Sigma, UK) for CYP450-1A1 and CYP450-3A4, respectively. Aggregates were then incubated for 72 h at 37°C/5% CO 2 (Matsuda et al. 2002; Ringel et al. 2005 ). The induction medium was then discarded and aggregates were washed with phosphate-buffered saline prior to addition of fresh media containing 100 µM of the luminogenic substrates luciferin-CEE (for the P450-1A1 cytochrome) and luciferin-PFBE (for the P450-3A4 cytochrome) provided by the P450-Glo™ assay kits. Aggregates were subsequently incubated for 3 h at 37°C/5% CO 2 . Fifty microliters of media from each well was then transferred to an opaque white 96-well plate and 50 µl of the luciferin detection reagent (provided by the respective kits) was finally added to initiate a luminescent reaction. The plates were further incubated for 20 min at room temperature. Luminescence was read on a FLUOstar Optima microplate multi-detection reader (BMG Labtech, Aylesbury, UK).
Normalization of data
Data obtained from the glucose, lactate, and CYP450 assays were calibrated against the number of cells in the aggregates on the sampling day, using the WST-1 Cell Proliferation Assay Kit (Roche Applied Science, Mannheim, Germany), as previously described (Bazou et al. 2008) . Briefly, on days 0, 1, 3, 7, and 10 in culture and after removal of the culture media for analysis of glucose, lactate, and CYP450-1A1/-3A4 concentrations, 10 μl of WST-1 reagent was added to the wells containing the encapsulated or the control, 3-D HepG2 aggregates in suspension. The plate was incubated for 4 h at 37°C/5% CO 2 and then read at 450 nm using a microtiter plate reader (Anthos Lab Instruments). The number of cells in the samples was calculated by substituting the absorbance of the samples into the equation of the standard curve generated for a single cell suspension of HepG2 cells.
Glutathione-S-transferase assay
On days 0, 1, 3, 7, and 10 in culture, encapsulated as well as control 3-D HepG2 aggregates were collected by centrifugation (2,000×g, 10 min at 4°C). The cell pellet was then homogenized in cold buffer (provided by the kit). Samples were centrifuged at 10,000×g for 15 min at 4°C. The supernatant was then removed and stored at −80°C prior to analysis using the glutathione-S-transferase assay kit according to the manufacturer's instructions (Immundiagnostik, Bensheim, Germany).
Protein determination
Total protein concentration of cell lysates from the glutathione-S-transferase assay was measured with the bicinchoninic acid (BCA) protein assay kit from Pierce (Thermo Scientific, Rockford, USA), which is based on BCA for the colorimetric detection and quantification of total protein, as per manufacturer's instructions.
Statistical analysis
The data presented here are shown as mean ± standard error of mean. Each experiment was repeated at least three times, each carried out in triplicates and representative data are presented (n=9). Analysis of means was performed with a two-tailed two sample t test (Minitab 13.0). Where data were not normally distributed or of unequal variance, the Mann-Whitney test was performed. Differences were considered significant at P values less than 0.05.
Results
In situ characterization of 3-D aggregate growth
HepG2 cells moved into the optically focused nodal plane of the ultrasound trap within 1 s of initiation of sonication. A small aggregate had formed 20 s later at the central region of the nodal plane. The growing aggregate had a closely packed morphology, consistent with our previous observations (Bazou et al. 2005a (Bazou et al. , 2008 Edwards et al. 2007) . Within 2 min of initiation of ultrasound, an aggregate was fully formed, as characterized by the absence of free single cells from the field of view; 3 min later, sonication was terminated and the aggregate was slowly recovered from the trap and finally encapsulated in 2% alginate/5 mM CaCl 2 , as previously described (Bazou et al. 2008 ).
For all experiments described in this study, three different aggregates were assessed for every time point, i.e., a total of 30 aggregates were generated (control and encapsulated), for every set of experiments (n=3 for every time point examined). A typical example of a 3-D HepG2 aggregate encapsulated in alginate in a well of a 96-well tissue culture plate is shown in Fig. 1a (side view) and b (top view; Bazou et al. 2008) . The selected hydrogel (2% alginate/5 mM CaCl 2 ) was rigid enough and did not allow sedimentation of the aggregates at the bottom of the wells over the 10-day culture period (Bazou et al. 2008 ).
Detection of hypoxia
On day 0 (i.e., approximately 5 h after aggregate formation and encapsulation), hypoxia was not detected by confocal microscopy in aggregates (control and encapsulated) grown under 95% O 2 or in the hypoxic chamber. A day later (day 1) HIF-1α showed strong perinuclear accumulation ( Fig. 2a; arrows) in aggregates (control (data not shown) and encapsulated) maintained under hypoxic conditions, which persisted over the following 9 days in culture. Figure 2b shows a low magnification micrograph of a hypoxic aggregate after 3 days in culture (the field of view is different than that shown in Fig. 2a ). This staining pattern was detected throughout the entire depth of the aggregates.
In contrast, aggregates (control (data not shown) and encapsulated) grown under 95% O 2 did not show signs of hypoxia in their central core after 1 day in culture (Fig. 2c ii, i has been included to confirm the presence of an aggregate through propidium iodide staining). On day 3 in culture, little HIF-1α staining was detected at the central core of the aggregates (Fig. 2d, arrows) and remained as such throughout the culture period. However, the intensity of the staining as assessed by microscopic observations was much lower than that observed for aggregates grown under 5% O 2 . HIF-1α was not detected at the outer parts of the aggregates. It is noted that the central core of the aggregates was identified by confocal microscopy as the confocal sections half way through the depth of the aggregates. No detectable difference could be observed by confocal microscopy in the HIF-1α distribution pattern between day 1 and day 10 samples (data not shown) of encapsulated aggregates grown under 5% O 2 and day 3 and day 10 samples (data not shown) of control aggregates grown under 95% O 2 .
Detection of cytokeratin-18
Encapsulated as well as control (data not shown) 3-D HepG2 aggregates in suspension, demonstrated striking a The alginate hydrogel was placed at the bottom of the well, the aggregate was immersed in it (arrow) and finally culture media was placed on top. b Aggregates occasionally folded during recovery from the ultrasound trap and encapsulation in alginate hydrogel. The arrow is pointing towards the darker area of the aggregate indicating that the edges of the aggregate have folded resulting in a much higher number of cell layers in this particular aggregate part. Scale bar in a is 100 μm and b 170 μm. Reproduced with permission from Toxicology in Vitro pericellular C-18 staining on day 0 in culture ( Fig. 3a ; the orthogonal sections are also shown (x-and y-axes)) with a reduction of staining seen towards the cytoplasm. This staining pattern was established on day 0 and remained as such over the following 9 days in culture. C-18 distribution appeared homogeneous throughout the aggregate's depth ( Fig. 3b ; 3-D reconstruction where aggregate has been rotated by 15°). No detectable difference could be observed by confocal microscopy in the C-18 distribution pattern between day 0 and day 10 samples (data not shown) of encapsulated and control aggregates (data not shown).
Glucose production/secretion in encapsulated 3-D HepG2 aggregates Glucose production in encapsulated as well as control, 3-D HepG2 aggregates in suspension over 10 days in culture is shown in Fig. 4a . Encapsulated 3-D HepG2 aggregates on day 0, i.e., approximately 5 h after aggregate formation and encapsulation, rapidly consume glucose contained in the culture media (45.6± 6.3 nmol/10,000 cells). A day later (day 1), encapsulated aggregates start secreting glucose (55± 18.4 nmol/10,000 cells; P=0 for day 1 vs. day 0), while up to day 10, significantly more glucose is consumed (P=0 for day 10 vs. day 1; Fig. 4a ). On the other hand, nonencapsulated 3-D HepG2 aggregates in suspension rapidly produce glucose (day 0; 18.5± 4.3 nmol/ 10,000 cells); however, at day 1 they lose this ability (even though the amounts of glucose were found not to differ significantly (P=0.396 for day 1 vs. day 0)), and keep consuming glucose for the remaining 9 days in culture ( Fig. 4a; P=0 .761 for day 10 vs. day 1). Lactate secretion in encapsulated 3-D HepG2 aggregates Similar patterns of lactate production were observed for control and encapsulated 3-D aggregates (Fig. 4b) . Figure 4b shows that initially, from day 0 to day 3, there is a significant increase (P=0.005 and 0.044 for the encapsulated and control aggregates, respectively) in the amount of lactate released by encapsulated and control aggregates. On day 7, a distinct decline is observed in lactate release in encapsulated aggregates (P=0.022 for day 7 vs. day 3), whereas for control aggregates over 10 days in culture. Results are mean of three independent experiments each carried out in triplicates. Error bars represent one standard error of the mean aggregates this decline was non-significant (P=0.109; Fig. 4b ). The subsequent reduction on day 10 to 0.3± 0.05 nmol/10,000 cells (encapsulated) and 0.17± 0.01 nmol/10,000 cells (control; P=0.298 and 0.307 for the encapsulated and control aggregates, respectively) was non-significant (Fig. 4b) .
Phase I metabolism: recovered cytochrome P450-1A1 and P450-3A4 activities
The production amount of D-luciferin at different time points during aggregate culture represents the kinetics of cell CYP450-1A1/CYP450-3A4 activities. It is noted that the time points shown in Fig. 5a , b correspond to the day that the two inducers, 3-MC and RIF, were added to the cell cultures (i.e., for an aggregate being in culture for example, for 1 day (day 1 sample), CYP450-1A1/CYP450-3A4 activities were assessed 3 days later, following a 72-h incubation with 3-MC or RIF). Fig. 5a , the CYP450-1A1 enzyme activity of encapsulated 3-D HepG2 aggregates was greatly enhanced on day 1 (0.06±0.008 µM D-luciferin/10,000 cells) compared to day 0 (0019±0.006 µM D-luciferin/10,000 cells; P = 0.018). A significant decrease to 0.005 ± 0.0006 µM D-luciferin/10,000 cells in the next 9 days (P=0.039) followed. Control, non-encapsulated 3-D HepG2 aggregates revealed a similar CYP450-1A1 activity (Fig. 5a) ; however, the enzyme activity on day 0 (0.01±0.002 µM D-luciferin/10,000 cells) was almost half that of encapsulated aggregates (Fig. 5a) . CYP450-3A4 activity CYP450-3A4 activity of encapsulated 3-D HepG2 aggregates on day 0 in culture was 0.141 ± 0.015 µM D-luciferin/10,000 cells (Fig. 5b) . Over the following 6 days, a significant increase in P450-3A4 activity occurred (P=0.021 for day 7 vs. day 0), while at day 10 CYP450-3A4 activity fell to initial levels (0.13 ± 0.035 µM D-luciferin/10,000 cells; P=0.004 for day 7 vs. day 10; Fig. 5b) . As was the case for the CYP450-1A1 activity, non-encapsulated aggregates followed a similar trend with regards to their CYP450-3A4 activity with a non-significant decrease occurring from day 7 to day 10 in culture (P=0.114; Fig. 5b ).
CYP450-1A1 activity As shown in
Phase II metabolism: glutathione-S-transferase activity
The glutathione-S-transferase activity of encapsulated and control (non-encapsulated) 3-D HepG2 aggregates is shown in Fig. 6 . Similar patterns of glutathione-S-transferase activity were observed for control (non-encapsulated) and encapsulated 3-D aggregates (Fig. 6 ), while this activity remained constant over the 10-day culture period (for day 10 vs. day 0, P=0.355 and 0.241 for the encapsulated and control aggregates, respectively).
Discussion
This paper presents alginate encapsulation of preformed high-density 3-D HepG2 cell aggregates that guarantees good maintenance of representative biochemical properties. The ultrasound trap allows the generation of uniformly shaped and sized aggregates; at the cell concentration used here, i.e., 4×10 6 cells/ ml, 3-D aggregate diameter was ∼2.6 mm and aggregate thickness was 90-100 µm (Fig. 1a, b ; Bazou et al. 2008) . A limitation of the system presented here is that only one aggregate can be formed each time; an aggregate in the single half wavelength ultrasound trap is formed within 3-5 min and the transfer to the wells of a 96-well plate for 3-D culturing requires less than 60 s. Therefore, the overall process is longer than 6 min. For every set of experiments, 30 aggregates are formed, thus the time required to form all the aggregates is, on average, 180 min (3 h). This time frame is still quite competitive to the time required for pellet or spheroid cultures. Kuznetsova et al. (submitted for publication) have reported on a plane cylindrical multi-wavelength resonator for the simultaneous formation of up to 100 3-D cell aggregates; generating 100 aggregates in 5 min will effectively reduce the aggregate preparation time from 3 h to 10 min, thus allowing for the rapid screening of multiple pharmaceutical agents. The restraint of the multi-wavelength system, however, is that aggregates are not of uniform dimensions; hence, care should be taken for data interpretation.
Ultrasound-formed encapsulated high-density 3-D HepG2 aggregates, besides their "technical" advantages (3-D structure, rapid formation, mechanical stability), also demonstrated good functionality of liver-specific biomarkers including CYP450-1A1 and CYP450-3A4, glutathione-S-transferase expression, Fig. 6 Kinetics of glutathione-S-transferase activity in encapsulated and control 3-D HepG2 aggregates over 10 days in culture. Results are mean of three independent experiments each carried out in triplicates. Error bars represent one standard error of the mean C-18 expression, glucose, and lactate release; furthermore, hypoxia was detected at very low levels at the central core of the aggregates after 3 days in culture.
Glucose secretion is a liver-specific function . Hepatocytes in liver spheroids retain the ability to secrete glucose spontaneously under no influence from neural or hormonal stimuli . HepG2 cells, on the other hand, cultured as either monolayer or spheroids have been shown not to possess this liver-specific function . The present study, however, demonstrated that encapsulated 3-D HepG2 aggregates release glucose into the media (Fig. 4a) , although this ability is exhibited only after 1 day in culture. In contrast, control aggregates secrete glucose into the media soon after their formation (i.e., within 5 h), and as was the case with encapsulated aggregates, they lose this ability in the ensuing 9 days in culture (Fig. 4a) . The liver is the major organ involved in biotransforming galactose into glucose (Xu and Purcell 2006) , and this function is retained in liver spheroids; furthermore, glucose can be synthesized from other sources such as pyruvate , lactate (Sumida et al. 2005) , as well as from a range of glucogenic amino acids such as serine, threonine, glutamine, etc. through gluconeogenesis (Brosnan 2003) . The medium used here for HepG2 aggregate culture contained glucose as the major energy source. Taking into account that pyruvate was not contained in the defined media, it is reasonable to assume that HepG2 aggregates synthesized glucose using glucogenic amino acids contained in the media, through gluconeogenesis. In addition, HepG2 aggregates did not take up lactate as it was not contained in the media; instead lactate was released from the aggregates and accumulated in the media. Ma et al. (2003) reported that liver cells undergo a period of biochemical and functional instability within the first days in culture and so the release of glucose into the media by HepG2 aggregates (encapsulated and control) could be a spontaneous process; however, it is important to emphasize that within 10 days in culture encapsulated and control 3-D HepG2 aggregates have sufficient glucose for their metabolic activities.
Anaerobic glycolysis by encapsulated and control 3-D HepG2 aggregates was measured as a function of extracellular lactate levels. It is known that increased lactate release is associated with low oxygen levels (Schmeisch et al. 2005 ). The present study showed that both control and encapsulated 3-D HepG2 aggregates constantly release lactate in the media, while more lactate is secreted after 3 days in culture (Fig. 4b ). This indicates a more hypoxic environment and hence a higher rate of anaerobic glycolysis (Khattak et al. 2006) . This may be due to the lower oxygen gradient in the deeper layers of the aggregates leading to the production of more lactate (Xu and Purcell 2006) . We have previously found that the proliferation index of 3-D HepG2 aggregates (control and encapsulated) is at its minimum after 3 days in culture (Bazou et al. 2008) , thus correlating well with the present findings. Bader et al. (1999) also reported that oxygen demand in sandwich rat hepatocyte cultures is highest during the initial days in culture, whereas this demand reaches physiological levels in long-term cultures, in accordance with the results reported here (Fig. 4b) . The hypoxia results presented in this study are also in good agreement with the above observations. HIF-1α labeling in 3-D HepG2 aggregates (control and encapsulated) grown under 95% O 2 was detected in the perinuclear region (Zheng et al. 2006 ) after 3 days in culture (Fig. 2d) , at which time point lactate levels are at their maximum (Fig. 4b) , while no further detectable change could be observed over the ensuing 7 days in culture. It has been appreciated that there are limitations with cell encapsulation devices due to internal oxygen mass transfer limitations (Khattak et al. 2006; Chin et al. 2008) ; however, for the selected hydrogel and for the examined aggregate sizes presented here, hypoxia was detected at very low levels. It may be that the discoid structure of ultrasound-formed aggregates allows for a better diffusion of oxygen and nutrients to their central core. Furthermore, similar levels of hypoxia were detected between control (non-encapsulated) and encapsulated aggregates maintained under 95% O 2 , suggesting that hypoxia is related to the thickness of the aggregates rather than to the material properties of the alginate hydrogel.
Cytokeratins are members of the intermediate filament family of proteins that are found primarily in epithelial tissues. Cytokeratins interact to form filamentous cytoplasmic networks that run from the surface of the nucleus to the plasma membrane thus providing mechanical integrity to the cells (Nakamishi et al. 2002) . The results shown in Fig. 3 are difficult to reunite with an exclusive intracellular distribution of C-18. Wells et al. (1997) also demonstrated pericellular C-18 staining in rabbit and human liver sections, while the presence of C-18 on the cell surface of HepG2 cells was confirmed with radiolabeled antibodies. In the present study, 3-D encapsulated HepG2 cells were positive for C-18 over the 10-day culture period and thus retain this liver-specific feature, in line with several reports where the expression of this hepaticspecific marker is examined (Nakamishi et al. 2002; Wei et al. 2008) .
Drug metabolism in the liver usually involves two enzymatic steps commonly referred to as phase I and phase II (Langsch and Bader 2001) . Most authors only describe the expression of cytochromes P450, belonging to phase I of drug metabolism in liver, whereas less attention has been paid to the expression of phase II enzymes. However, phase II enzymes such as glutathione-S-transferases (GSTs) are important for the detoxification and for the activation of many xenobiotics (Cantelli-Forti et al. 1998; Wilkening et al. 2003; Westernik and Schoonen 2007) .
Our results showed that the levels of detoxificatory function for the CYP450-1A1 reach their maximum on day 1 of culture, at levels comparable to those reported by Westernik and Schoonen (2007) followed by a progressive reduction to basal levels in the following 9 days even after treatment with inducers (Schuetz et al. 1993 ). Diminution of CYP450-1A1 function in hepatocytes encapsulated in alginate-poly-l-lysine-alginate capsules has been reported by Coward et al. (2004) and Wang et al. (2000) , while the mRNA expression of several P450s has been shown to progressively decline in monolayers of HepG2 cells over 20 days in culture (Maruyama et al. 2007 ). Wang et al. (2000) ascribed this loss of function to extracellular calcium toxicity sustained during the gelling of capsules. Nevertheless, further work is required to elucidate this suggestion. CYP450-3A4 activity, on the other hand, was upregulated in a time-dependent manner, gradually increasing from day 0 to day 7, while a sudden reduction to initial levels occurred on day 10 (Fig. 5b) . Ogino et al. (2002) and Harmsen et al. (2008) reported that CYP450-3A4 is scarcely expressed and is nonresponsive to RIF treatment, while Ohno et al. (2008) found that CYP450-3A4 activity of HepG2 cells cocultured with bovine pulmonary artery endothelial cells increases after day 10 of layering and continues to increase until day 21 in culture. Nevertheless, the results presented here are in keeping with those previously reported by Maruyama et al. (2007) and Ushui et al. (2003) . Hewitt and Hewitt (2004) attributed this inconsistency to differences in cell source and/or culture conditions. In contrast, GST activity was at more physiological levels (i.e., levels similar to those of primary hepatocytes (Otto et al. 2008) ) and remained constant over 10 days in culture. Due to the low CYP450 enzyme levels, and more physiological levels of GSTs, there might be a balance towards the detoxification process of some compounds (Rodriguez-Antona et al. 2002; Otto et al. 2008 ). In the context of drug toxicity assays, it has been suggested that pre-stimulating HepG2 cells with aryl hydrocarbon receptor activators before performing cytotoxicity assays might lead to a better prediction of toxicity (Westernik and Schoonen 2007) .
The results presented here consistently show that the peak synthetic and detoxificatory functions of encapsulated aggregates occur during the first days in culture (day 1-day 3). Table 1 summarizes the liver-specific parameters of the encapsulated aggregates examined in this study as well as in a previous study by Bazou et al.
Examined liver-specific activity
Day in culture at which activity is at its maximum Bazou et al. (2008) The day in culture at which HepG2 aggregates show their maximum activity is also presented a Bazou et al. (2008) b Present study (2008) . In contrast, it has previously been shown (Bazou et al. 2008 ) that cell viability and cell proliferation did not deteriorate over the 10-day culture period, in line with the report by Damelin et al. (2004) . Khalil et al. (2001) attributed this behavior to potential diffusion difficulties resulting in secreted proteins becoming trapped within spheroids which in turn might lead to down-regulation of protein synthesis. von Allmen et al. (1991) , on the other hand, showed that in large spheroids detoxification can be demonstrated by removal of substrate but not by appearance of product and have also argued that diffusion may limit appearance of hepatocyte products above a critical size. However, our results showed that non-encapsulated aggregates also show progressive reduction of some of the biochemical markers studied here, suggesting that a physical explanation based on delayed diffusion is unlikely.
In conclusion, ultrasound-formed 3-D encapsulated HepG2 aggregates in culture are attractive as a novel cell system to provide guidance on human drug toxicity. Barile et al. (1994) had stated the good predictability of the in vitro tests of mammalian cell cultures towards the human toxicity dosing. More recently, in the European Centre for the Validation of Alternative Methods workshop, it was reported that the HepG2 cell system is a useful in vitro model for detecting environmental and human dietary genotoxicants, anti-and co-genotoxicants (Kirkland et al. 2007) , as it has the potential to discriminate between structurally related carcinogens and non-carcinogens, as well as between genotoxic and non-genotoxic carcinogens using gene expression profiling (van Delft et al. 2004) . Furthermore, HepG2 cells were reported to give fewer false-positive results in relation to other cell lines (Kirkland et al. 2007) .
The ability to rapidly, reliably, and reproducibly form uniformly shaped and sized 3-D aggregates that retain liver-specific properties is undoubtedly of high interest in the drug development field.
